EUVIMEDEUVIMED entdecken
Crossref

Human-Relevant Microphysiological Systems: Evidence for Defined Contexts of Use

Minseo Byeon iD, Eunseo Park iD, Jihoon Ko iD

International Journal of Stem Cells · 20.08.2026

DOI: 10.15283/ijsc26088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Stem Cells, online erschienen am 20.08.2026. Verfasst von Minseo Byeon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of BioNano Technology, Gachon University, Seongnam, Korea. Gefördert von: Gachon University, Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA Modernization Act has accelerated the transition from animal-based testing toward human-relevant new approach methodologies in drug development, shifting attention from technological feasibility to regulatory implementation. Among these approaches, microphysiological systems (MPS) can generate evidence that more directly reflects human physiology, but their regulatory readiness varies substantially across applications. This Review summarizes recent regulatory developments and evaluates the readiness of major organ-specific and multi-organ MPS. Liver MPS have advanced furthest through quantitative benchmarking, industrial adoption and sustained regulatory engagement, whereas kidney, lung, gastrointestinal, tumor, nervous system and multi-organ models remain limited by varying degrees of standardization, independent validation and clearly defined regulatory use. Across applications, major barriers include insufficiently specified contexts of use, limited human benchmark data, inadequate multicenter reproducibility, manufacturing variability and fragmented data infrastructure. We discuss priorities for overcoming these barriers, including performance-based standards, quality-controlled manufacturing, auditable data systems and earlier coordination among technology developers, end users and regulatory authorities. Patient-derived and stem cell-derived models, artificial intelligence and digital twins may further extend the scope of MPS, but their value will depend on transparent validation and integration with complementary evidence. Regulatory adoption is likely to proceed incrementally, with MPS initially supporting defined decisions as complementary evidence and replacing conventional studies when their performance and uncertainty are sufficiently characterized.

Schlagwörter

Stichwörter der Autor:innen

Animal testing alternativesDrug developmentDrug evaluationMicrophysiological systemsOrganoidsToxicity testspreclinical

Autor:innen und Institutionen

  • Department of BioNano Technology, Gachon University, Seongnam, Korea.

ORCID-Profile: Minseo Byeon, Eunseo Park, Jihoon Ko

Förderung

  • Gachon University
  • Ministry of Science and ICT

Zitieren

APA

Byeon, M., Park, E., & Ko, J. (2026). Human-Relevant Microphysiological Systems: Evidence for Defined Contexts of Use. International Journal of Stem Cells. https://doi.org/10.15283/ijsc26088

Vancouver

Byeon M, Park E, Ko J. Human-Relevant Microphysiological Systems: Evidence for Defined Contexts of Use. International Journal of Stem Cells. 2026. doi:10.15283/ijsc26088

BibTeX
@article{Byeon2026,
  author = {Byeon, Minseo and Park, Eunseo and Ko, Jihoon},
  title = {Human-Relevant Microphysiological Systems: Evidence for Defined Contexts of Use},
  journal = {International Journal of Stem Cells},
  year = {2026},
  doi = {10.15283/ijsc26088}
}
Kostenlos starten →